Free consultation for international patients
English
WhatsApp [email protected]
Treatments

Cancer treatment in China

Access to new cancer therapies and high-volume oncology centres in Beijing and Shanghai, with appointments arranged as soon as possible.

China has become one of the world’s busiest places for cancer research. Large hospitals in Beijing and Shanghai treat a very high number of patients each year, run many clinical trials, and use several cancer medicines that have been approved in China before other countries.

Why patients come to China for cancer care

  • New medicines. Some targeted therapies and immunotherapies are available in China earlier than elsewhere.
  • Experience at scale. Leading oncology centres see a very large volume of cases, including rare cancers.
  • Prompt arrangements. We arrange consultations, scans and admission as soon as possible.

How we help

We review your records, find the right hospital for your diagnosis, and stay with you from the first consultation to your return home: interpreters at every appointment, help with admissions and paperwork, and follow-up after you leave.

By condition

Questions patients ask

Can I get a treatment opinion before travelling?

Yes. Send us your medical records and we arrange a remote review by a Chinese oncology team first, so you only travel if a treatment plan makes sense.

Do I need to translate my medical records?

No. Our medical translators prepare Chinese versions of your reports and scans for the hospital.

Can a family member come with me?

Yes. We arrange visas, flights and accommodation for you and your companions.

Related news

Research

Effect of Chinese medicine compound on intestinal bifidobacteria recovery and CD4+ T-Cell activation in postoperative chemotherapy patients with breast cancer

7 October 2026 · PubMed
Oncology

Why Is Ovarian Cancer Often Mistaken for a Stomach Ailment? Lan Chunyan: A Silent Killer That Can Be Prevented and Treated

30 September 2026 · Xinhua Health
Research

Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience

1 September 2026 · PubMed
Oncology

Ovarian cancer 'Chinese protocol' draws overseas patients as multidisciplinary team performs precise 'bomb disposal' for Pakistani patient

29 July 2026 · Fudan University Shanghai Cancer Center